Nuhad K. Ibrahim, MD

Articles by Nuhad K. Ibrahim, MD

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

July 5th 2023

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.

Latest Updated Articles

Nuhad K. Ibrahim, MD

Articles by Nuhad K. Ibrahim, MD

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

Latest Updated Articles

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows